Positive P3 data we have a chance in a good market to see $15+ within 2 weeks as the analyst raise price targets ect............. There will be an analyst who will build a case on a discounted cash flow basis for a $25 PPS. you can all bet on that happening.
Trius only has 50 million shares outstanding. TSRX's drug Tedizolid will surplant the standard-of-care drug, Linezolid, manufactured by Pfizer. TSRX's drug is more efficacious and easier to administer to patients. In 2010 Pfizer achieved Linezolid revenues of 1.2 billion. Once TED is approved revenues should exceed 2 billion a year for starts. Pfizer will be forced to buy Trius. At 2 billion a year revenue with 50 million shares outstanding and using a 10-15 X's multiple TSRX should trade at $250-$300 pps. This should exceed Regeneron as a market cap comparison.